Amphastar P (AMPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amphastar P (AMPH) has a cash flow conversion efficiency ratio of 0.062x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($47.84 Million) by net assets ($773.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Amphastar P balance sheet independence to measure how much of total assets are equity-financed.
Amphastar P - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Amphastar P's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check AMPH cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Amphastar P Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amphastar P ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China West Construction Group Co Ltd
SHE:002302
|
-0.013x |
|
Aeva Technologies, Inc. Common Stock
NASDAQ:AEVA
|
2.083x |
|
Flowco Holdings Inc.
NYSE:FLOC
|
0.059x |
|
Blacksky Technology Inc
NYSE:BKSY
|
-0.029x |
|
Theravance Biopharma Inc
NASDAQ:TBPH
|
-0.020x |
|
Limbach Holdings Inc
NASDAQ:LMB
|
-0.040x |
|
Indus Holding AG
XETRA:INH
|
0.096x |
|
JM AB (publ)
ST:JM
|
-0.005x |
Annual Cash Flow Conversion Efficiency for Amphastar P (2012–2025)
The table below shows the annual cash flow conversion efficiency of Amphastar P from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Amphastar P (AMPH) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $788.80 Million | $156.12 Million | 0.198x | -32.08% |
| 2024-12-31 | $732.30 Million | $213.39 Million | 0.291x | +1.54% |
| 2023-12-31 | $639.42 Million | $183.50 Million | 0.287x | +70.12% |
| 2022-12-31 | $528.66 Million | $89.18 Million | 0.169x | -23.30% |
| 2021-12-31 | $445.52 Million | $97.99 Million | 0.220x | +72.35% |
| 2020-12-31 | $448.72 Million | $57.27 Million | 0.128x | +30.65% |
| 2019-12-31 | $427.53 Million | $41.76 Million | 0.098x | -6.81% |
| 2018-12-31 | $364.36 Million | $38.19 Million | 0.105x | -9.82% |
| 2017-12-31 | $337.33 Million | $39.21 Million | 0.116x | -0.75% |
| 2016-12-31 | $329.25 Million | $38.56 Million | 0.117x | +224.01% |
| 2015-12-31 | $295.51 Million | $10.68 Million | 0.036x | -51.61% |
| 2014-12-31 | $281.86 Million | $21.05 Million | 0.075x | -39.48% |
| 2013-12-31 | $251.54 Million | $31.04 Million | 0.123x | +1845.92% |
| 2012-12-31 | $233.44 Million | $-1.65 Million | -0.007x | -- |
About Amphastar P
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mi… Read more